osimertinib
astrazeneca
[]
 it s 43% among those who got subsequent treatment. among all patients, it s 23%. don t know how many of them were eligible to receive osi but didn t get it. 
Personal account. Med Onc. Associate Prof. @queensoncology @QueensuPHS. #cancerpolicy #cancergroundshot. Pubs: https://t.co/FTRPKNykq3 Talks- https://t.co/anav3AIZjO